NGEN today

$1.63+$0.28 (+20.74%)close Nov 12, 2026

Trend

DailyUptrend (starting)

4 hourStrong Bullish

1 hourStrong Bullish

15 minLeaning Bearish

5 minStrong Bullish

Daily trend turns down below $0.05

Key levels

Resistance$1.84

Resistance$1.70

Support$1.58

Support$1.28

NERVGEN PHARMA CORP. (NGEN)

$1.63+0.28 (+20.74%)

WATCHLISTGrade: BRisk: HIGH

1D 5D1M1Y 5Y MaxSign up for all timeframes

High1.63

Low1.36

Open1.38

Volume2.22M

Avg Vol443K

VWAP1.44

30d High1.81

30d Low1.32

30d Chg-8.43%

See full chart with real-time data

What Is the Price Target for NGEN?

SEPT Low Target

$10.00

SEPT Mid Target

$12.50

SEPT High Target

$15.00

Analyst Consensus

$12.50

Current: $1.66Upside: +653.0%Confidence: 40%Method: Analyst Consensus

Is NGEN a Buy or Sell Right Now?

Investability Score

WATCHLIST12-18 months

News summary · last 30 days

Nov 12▲ UpFda approval successProduct3 articles

NervGen Pharma shares surged 18.12% to close at $1.63 after the FDA granted breakthrough therapy designation to its experimental drug NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, a status designed to speed development and review for serious conditions. The company also announced that its Phase 3 RESTORE registrational trial is now enrolling approximately 150 participants across sites in the United States and Canada. Both developments are bullish catalysts, with the FDA designation carrying high impact and the trial enrollment providing a medium-impact positive signal. The stock traded between $1.36 and $1.63 on volume of over 2.2 million shares, reflecting strong investor response to the news.

Thesis

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NGEN.

Start Free Trial →

Is NGEN Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$12.50

Moat Score

NONE

3/9

Piotroski Score

-4.6

Altman Z-Score

What Is Smart Money Doing with NGEN?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

NGEN Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

-66.13%

FCF Growth YoY

N/A%

Revenue Trend

UNKNOWN

Dark Pool Trades for NGEN

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for NGEN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
24:33:13	$1.67	3,000	$$5K	SELL
23:13:22	$1.61	1,600	$$3K	SELL
23:08:45	$1.65	1,000	$$2K	SELL
23:02:50	$1.69	5,000	$$8K	BUY
22:56:04	$1.68	2,300	$$4K	BUY

5 dark pool trades shown · $$22K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for NERVGEN PHARMA CORP. (NGEN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

NGEN — frequently asked questions

What is NGEN stock price today?

NERVGEN PHARMA CORP. (NGEN) is at $1.63, up 20.74% (+$0.28) at the Nov 12, 2026 close.

Why is NGEN stock up today?

Nov 12, 2026: NervGen Pharma shares surged 18.12% to close at $1.63 after the FDA granted breakthrough therapy designation to its experimental drug NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, a status designed to speed development and review for serious conditions. The company also announced that its Phase 3 RESTORE registrational trial is now enrolling approximately 150 participants across sites in the United States and Canada.

What is the NGEN price target?

The average analyst price target for NGEN is $12.50, ranging from $10 to $15, based on 2 analysts. Latest: HC Wainwright & Co. maintains on Jul 14, 2026.

What do analysts rate NGEN?

Analyst ratings for NGEN: 0 Buy, 2 Hold, 0 Sell — consensus Hold.

Did NGEN beat earnings?

NGEN last reported on Aug 13, 2026: EPS -$0.37 vs -$0.06 expected — a miss of 510.6%.

What are NGEN support and resistance levels?

Support: $1.58, $1.28. Resistance: $1.70, $1.84, $1.98.

What are insiders doing with NGEN?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on NGEN?

Nov 12, 2026: NervGen's NVG-291 earns FDA breakthrough tag for chronic spinal cord injury · Nov 12, 2026: NervGen says Phase 3 RESTORE study is enrolling about 150 participants in US and Canada · Nov 12, 2026: FDA gives breakthrough status to NervGen's NVG-291 for chronic cervical spinal cord injury